NCT06956807尚未招募1 期
First in Human Open Label Multicentre Clinical Trial to Evaluate the Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells in Patients With Ischaemic Left Ventricular Dysfunction Scheduled to Undergo Coronary Revascularisation Surgery
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- Viscofan
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- combination of MACCEs at all follow up visits during the first year after treatment
研究概览
简要总结
- The Cardiomesh II clinical trial is a phase I open label study intended to enrol 10 patients to evaluate the safety and efficacy of surgical epicardial implantation of a membrane seeded with allogeneic adipose tissue derived stem cells in patients scheduled to undergo coronary revascularisation surgery and at high risk of developing heart failure.
- The primary objective of the study is to evaluate the safety of surgical implantation of this membrane in patients with large ischaemic myocardial scars scheduled to undergo coronary revascularisation surgery. The secondary objective is to investigate the efficacy of the above treatment in terms of reduction of scar size and ventricular function parameters.
详细描述
- The clinical trial CARDIOMESH II aims to attenuate adverse remodelling of the left ventricle, which is the main cause of death in ischaemic heart disease, through the development of a new regenerative therapy consisting of the combination of allogeneic adipose derived stem cells with bovine derived collagen membranes to promote repair of damaged myocardium. This is predicted to achieve a 10% reduction in mortality related to ischaemic heart failure.
- Specifically, the working hypotheses of the project are:
- Surgical implantation of a membrane containing allogeneic adipose derived stem cells in patients with large myocardial scars scheduled to undergo coronary revascularisation surgery is technically feasible.
- Surgical implantation of a membrane containing allogeneic adipose derived stem cells in patients with large myocardial scars scheduled to undergo coronary revascularisation surgery is safe in terms of the primary objective consisting of major adverse cardiac and cerebrovascular events (MACCEs).
- Surgical implantation of the aforementioned bioengineering product is safe in terms of cardiac effects and immunological analysis.
- Surgical implantation of this cellularised membrane shows beneficial effects in terms of efficacy measured by surrogate cardiac imaging parameters.
- Designed as an international phase I clinical trial to be conducted at two sites in two European countries, the purpose of the study is to establish the basic safety parameters and to obtain preliminary efficacy data on clearly established surrogate variables to undertake future larger scale trials focused on clinical efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients planning to undergo coronary revascularisation surgery within one month of study entry.
- •LVEF ≤45% by CMRI.
- •History of myocardial infarction at least 3 months prior to inclusion.
- •Scar covering at least 15% of the total left ventricular myocardial mass defined by late enhancement on CMRI.
排除标准
- •Participation in another clinical trial within 30 days prior to inclusion.
- •Prior treatment with cell or gene therapy.
- •Be a candidate for heart transplant at the time of study entry.
- •Diagnosis of acute myocardial infarction with 3 months prior to inclusion.
- •Need for urgent revascularisation surgery.
- •Strict contraindication for the use of CMRI (pacemaker or implantable automatic defibrillator carriers, previous reactions to gadolinium contrast, claustrophobia, cochlear implants, etc.).
- •Presence of uncontrolled ventricular arrhythmias (ventricular tachycardia or ventricular fibrillation) at the time of implant surgery.
- •Active systemic infection.
- •Women who are pregnant or breastfeeding.
- •Mental disease or psychological condition that impedes the subject from understanding the nature of the protocol and granting his/her consent
- •Advanced dementia according to the Barthel index.
- •History of primary or acquired immunodeficiency or on immunosuppressive therapy (within 3 months prior to inclusion or if the need for immunotherapy is foreseeable at any time during the study follow up).
- •Tumour disease, except that eradicated at least 5 years prior to inclusion in the study and without receiving chest radiotherapy. Completely eradicated non melanoma skin tumours (at any time) not requiring chest chemotherapy or radiotherapy are permitted.
- •History of autoimmune disease.
- •Stroke within 12 months prior to inclusion.
- •Respiratory compromise or need for home oxygen therapy.
- •Life expectancy of less than 1 year for any reason
结局指标
主要结局
combination of MACCEs at all follow up visits during the first year after treatment
时间窗: 12 months
combination of MACCEs at all follow up visits during the first year after treatment (after surgery, at 1, 3, 6, 9 and 12 months). MACCEs are defined as all cause death, myocardial infarction requiring target vessel revascularisation, hospitalisation for heart failure, cardiac tamponade or pericardial constriction, sustained ventricular tachycardia, ventricular fibrillation, and stroke.
次要结局
- Safety - Composite MACCE(12 months)
- Safety - Hematology parameters(12 months)
- Safety - Adverse Events(12 months)
- Safety - Biochemical blood parameters(12 months)
- Safety - New York Heart Association (NYHA) functional class(12 months)
- Safety - Minnesota Living with Heart Failure (MLHFQ) questionnaire(12 months)
- Safety - 6 minute walk test(12 months)
- Safety - Brain natriuretic peptide curve (Nt proBNP or BNP)(12 months)
- Safety - C reactive protein (CRP) levels(1 month)
- Safety - Incidence of subacute pericardial inflammation or constrictive physiology(12 months)
- Safety - Immunological analysis(1 month)
- Efficacy - Change in scar size(12 months)
- Efficacy - end systolic volume(12 months)
- Efficacy - end diastolic volume(12 months)
- Efficacy - ejection fraction(12 months)
- Efficacy - segmental contractility(12 months)
- Efficacy - segmental wall thickness(12 months)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid TumorsSolid TumorNCT05159388Servier Bio-Innovation LLC46
终止
1 期
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the OvaryNeoplasm, OvarianFallopian Tube CancerPrimary Peritoneal Cavity CancerAdenocarcinoma OvarySerous Adenocarcinoma of OvarySerous Adenocarcinoma of Primary PeritoneumHigh Grade Serous AdenocarcinomaPrimary Peritoneal CarcinomaNCT05538624Avenge Bio, Inc14
招募中
1 期
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849Advanced Solid TumorNCT057612231ST Biotherapeutics, Inc.151
终止
1 期
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null TumorsSoft Tissue SarcomaSynovial SarcomaNCT05355753C4 Therapeutics, Inc.49
招募中
1 期
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsAdvanced Solid TumorsGenital Neoplasm, FemaleUrogenital NeoplasmsNeoplasms by SitePapillomavirus InfectionEpstein-Barr Virus InfectionsCarcinomaNeoplasmsVulvar NeoplasmsVulvar DiseasesAbdominal NeoplasmLung NeoplasmNSCLC (Non-small Cell Lung Cancer)Colorectal CancerNCT05592626Marengo Therapeutics, Inc.366